Document is current
Any future updates will be listed below
-
Authors
Li, Zhaoyi
Zheng, De-Chong
Wang, Ruixiang
Ding, Qian
Zhu, Yi Zhun
-
Funding
Funding for this research was provided by:
Macau Science and Technology Development fund (FDCT 0012/2021/AMJ, 003/2022/ALC, 0092/2022/A2, 0144/2022/A3)
Shenzhen-Hong Kong-Macao Science and Technology Fund (SGDX20220530111203020)
- License Information
-
More Information
Article History
Received: 18 January 2025
Accepted: 2 July 2025
First Online: 23 July 2025
Declarations
:
: The original sources (Pricella Biotechnology Co., Ltd.) confirmed that there was initial ethical approval for the collection of human cells and that the donors signed informed consent forms. The use of animals in this study was approved by the Animal Ethics Committee of the Animal Center of the State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, and was conducted in accordance with the ARRIVE guidelines 2.0. The approved study is titled “Mechanism of mesenchymal stem cell-derived exosomes in improving heart failure”, with approval granted on May 12, 2022 (AL007/DICV/DIS/2022). All procedures were approved by the Medical Research Ethics Committee of Guangdong Provincial People’s Hospital. The research project titled “Study on the pathogenesis of heart failure” was approved on October 13, 2021 (KY-A-2021-414-02). Patients or their guardian(s)/legally authorized representative(s) provided written informed consent for their participation in the study and the use of their tissue.
: Not applicable.
: The authors declare that they have no competing interests.
